| Literature DB >> 33915078 |
Markus Breunig1, Jessica Merkle1, Martin Wagner1, Michael K Melzer2, Thomas F E Barth3, Thomas Engleitner4, Johannes Krumm5, Sandra Wiedenmann6, Christian M Cohrs7, Lukas Perkhofer1, Gaurav Jain4, Jana Krüger1, Patrick C Hermann1, Maximilian Schmid1, Tamara Madácsy8, Árpád Varga8, Joscha Griger4, Ninel Azoitei1, Martin Müller1, Oliver Wessely9, Pamela G Robey10, Sandra Heller1, Zahra Dantes11, Maximilian Reichert11, Cagatay Günes12, Christian Bolenz12, Florian Kuhn1, József Maléth13, Stephan Speier7, Stefan Liebau14, Bence Sipos15, Bernhard Kuster16, Thomas Seufferlein1, Roland Rad4, Matthias Meier17, Meike Hohwieler1, Alexander Kleger18.
Abstract
Personalized in vitro models for dysplasia and carcinogenesis in the pancreas have been constrained by insufficient differentiation of human pluripotent stem cells (hPSCs) into the exocrine pancreatic lineage. Here, we differentiate hPSCs into pancreatic duct-like organoids (PDLOs) with morphological, transcriptional, proteomic, and functional characteristics of human pancreatic ducts, further maturing upon transplantation into mice. PDLOs are generated from hPSCs inducibly expressing oncogenic GNAS, KRAS, or KRAS with genetic covariance of lost CDKN2A and from induced hPSCs derived from a McCune-Albright patient. Each oncogene causes a specific growth, structural, and molecular phenotype in vitro. While transplanted PDLOs with oncogenic KRAS alone form heterogenous dysplastic lesions or cancer, KRAS with CDKN2A loss develop dedifferentiated pancreatic ductal adenocarcinomas. In contrast, transplanted PDLOs with mutant GNAS lead to intraductal papillary mucinous neoplasia-like structures. Conclusively, PDLOs enable in vitro and in vivo studies of pancreatic plasticity, dysplasia, and cancer formation from a genetically defined background.Entities:
Keywords: CDKN2A; GNAS; IPMN; KRAS; PDAC; disease modelling; ductal pancreatic organoids; human pluripotent stem cells; in vitro differentiation; xenograft
Mesh:
Year: 2021 PMID: 33915078 PMCID: PMC8461636 DOI: 10.1016/j.stem.2021.03.005
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 25.269